| CAS ID: | 518048-05-0 |
| Molecular Formula: | C20H21FN6O5 |
| Molecular Weight: | 444.4 g/mol |
| Monoisotopic Mass: | 444.1557 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | RALTEGRAVIR | ISENTRESS HD | MK-0518 | ISENTRESS | RALTEGRAVIR POTASSIUM |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30) | See All |
| InChI Key: | CZFFBEXEKNGXKS-UHFFFAOYSA-N | |
| Smiles: | CN1C(=O)C(=C(N=C1C(C)(C)NC(=O)c2oc(C)nn2)C(=O)NCc3ccc(F)cc3)O | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT01231685 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 1, 2010 | Last Verified | September 21, 2016 |
| Sponsor | McGill University Health Center | ||
Trial Record 2
| ClinicalTrial ID | NCT01529749 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | February 9, 2012 | Last Verified | February 19, 2016 |
| Sponsor | Felipe Garcia | ||
Trial Record 3
| ClinicalTrial ID | NCT02210715 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Enrolling by invitation |
| First Received | August 7, 2014 | Last Verified | April 25, 2017 |
| Sponsor | McGill University Health Center | ||
Trial Record 4
| ClinicalTrial ID | NCT01289951 | Disease | Liver fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | February 4, 2011 | Last Verified | February 1, 2013 |
| Sponsor | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | ||
Trial Record 5
| ClinicalTrial ID | NCT01908660 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | July 26, 2013 | Last Verified | November 11, 2015 |
| Sponsor | Valme University Hospital | ||
| PubChem: | 54671008 |
| ChEMBL: | CHEMBL254316 |